Last reviewed · How we verify
PRAX-222 - Optional Ascending Doses — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
PRAX-222 - Optional Ascending Doses (PRAX-222 - Optional Ascending Doses) — Praxis Precision Medicines.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PRAX-222 - Optional Ascending Doses TARGET | PRAX-222 - Optional Ascending Doses | Praxis Precision Medicines | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PRAX-222 - Optional Ascending Doses CI watch — RSS
- PRAX-222 - Optional Ascending Doses CI watch — Atom
- PRAX-222 - Optional Ascending Doses CI watch — JSON
- PRAX-222 - Optional Ascending Doses alone — RSS
Cite this brief
Drug Landscape (2026). PRAX-222 - Optional Ascending Doses — Competitive Intelligence Brief. https://druglandscape.com/ci/prax-222-optional-ascending-doses. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab